Products for Research Use Only

Notoginsenoside Ft1

CAT: 0804-HY-N0910-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-N0910-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
NotoginsenosideFt1 is a saponin found in Panax notoginseng. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8+ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance[1][2][3][4][5][6][7][8].
CAS Number
155683-00-4
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Akt; Apoptosis; Calcium Channel; ERK; Estrogen Receptor/ERR; Ferroptosis; FXR; G protein-coupled Bile Acid Receptor 1; Glutathione Reductase (GR) ; mTOR; p38 MAPK; PI3K; Transmembrane Glycoprotein
Type
Natural Products
Related Pathways
Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; PI3K/Akt/mTOR; Stem Cell/Wnt; Vitamin D Related/Nuclear Receptor
Field of Research
Cancer; Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Notoginsenoside-Ft1.html
Purity
98.0
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C[C@@]([C@@]12C)(CC[C@@]3([H])C4(C)C)[C@@](C[C@@H](O)[C@]1([H])[C@]([C@](C)(O)CC/C=C(C)/C)([H])CC2)([H])[C@]3(CC[C@@H]4O[C@@](O[C@H](CO)[C@@H](O)[C@@H]5O)([H])[C@@H]5O[C@@](O[C@H](CO)[C@@H](O)[C@@H]6O)([H])[C@@H]6O[C@@](OC[C@@H](O)[C@@H]7O)([H])[C@@H]7O)C
Molecular Formula
C47H80O17
Molecular Weight
917.13
Precautions
H315, H319, H335
References & Citations
[1]Shen K, et al. Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways. Biochem Pharmacol. 2012 Sep 15;84 (6) :784-92.|[2]Gao B, et al. Platelet P2Y12 receptors are involved in the haemostatic effect of notoginsenoside Ft1, a saponin isolated from Panax notoginseng. Br J Pharmacol. 2014 Jan;171 (1) :214-23.|[3]Shen K, et al. Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. Biochem Pharmacol. 2014 Mar 1;88 (1) :66-74.|[4]Gao B, et al. p38 MAPK and ERK1/2 pathways are involved in the pro-apoptotic effect of notoginsenoside Ft1 on human neuroblastoma SH-SY5Y cells. Life Sci. 2014 Jul 17;108 (2) :63-70.|[5]Ding L, et al. Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice. Acta Pharm Sin B. 2021 Jun;11 (6) :1541-1554.|[6]Jeon Y, Kwon H, Chung T, Park YN, Kim SN, Park JY, Kang KS, Woo DY, Kim T, Kim YJ. Notoginsenoside Ft1 induces lysosomal cell death and apoptosis by inhibiting the PI3K/AKT/mTOR pathway in hepatocellular carcinoma. Biomed Pharmacother. 2025 Jul;188:118181. doi: 10.1016/j.biopha.2025.118181. Epub 2025 May 31. PMID: 40451034.|[7]Feng Y, Li Y, Ma F, Wu E, Cheng Z, Zhou S, Wang Z, Yang L, Sun X, Zhang J. Notoginsenoside Ft1 inhibits colorectal cancer growth by increasing CD8+ T cell proportion in tumor-bearing mice through the USP9X signaling pathway. Chin J Nat Med. 2024 Apr;22 (4) :329-340. doi: 10.1016/S1875-5364 (24) 60623-0. PMID: 38658096.|[8]Xiao X, Zhang J, Wu Y, Yang Q, Zhou Y, Yang J, Lang Y, Cai L, Ju X, Liu F. Mechanism of TGR5 in Ferroptosis of the Renal Tubular Epithelial Cells in Diabetes Mellitus and the Effect of Notoginsenoside Ft1. FASEB J. 2025 Jun 30;39 (12) :e70686. doi: 10.1096/fj.202402534R. PMID: 40549482.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Natural Products
Clinical Information
No Development Reported

Chemical Information

Notoginsenoside Ft1

Notoginsenoside Ft1 has been reported in Centella asiatica with data available.

CAS Number155683-00-4
PubChem CID91973814
IUPAC Name(2S,3R,4S,5R)-2-[(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol
Molecular FormulaC47H80O17
Molecular Weight917.1
XLogP2.5
Topological Polar Surface Area278
Hydrogen Bond Donor Count11
Hydrogen Bond Acceptor Count17
Rotatable Bond Count12
Heavy Atom Count64
Formal Charge0
Complexity1630
SMILES
CC(=CCC[C@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)C)C)O)C)O)C
InChI
InChI=1S/C47H80O17/c1-22(2)10-9-14-47(8,58)23-11-16-46(7)31(23)24(50)18-29-44(5)15-13-30(43(3,4)28(44)12-17-45(29,46)6)62-41-38(35(55)33(53)26(19-48)60-41)64-42-39(36(56)34(54)27(20-49)61-42)63-40-37(57)32(52)25(51)21-59-40/h10,23-42,48-58H,9,11-21H2,1-8H3/t23-,24+,25+,26+,27+,28-,29+,30-,31-,32-,33+,34+,35-,36-,37+,38+,39+,40-,41-,42-,44-,45+,46+,47+/m0/s1
InChIKey
LLXVPTXOKTYXHU-UGGLCNOCSA-N
Chemical Structure
2D Structure
2D structure of Notoginsenoside Ft1
CAS: 155683-00-4
CID: 91973814
Formula: C47H80O17
MW: 917.1
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight917.1
XLogP32.5
Hydrogen Bond Donor Count11
Hydrogen Bond Acceptor Count17
Rotatable Bond Count12
Exact Mass916.53955108
Monoisotopic Mass916.53955108
Topological Polar Surface Area278 Ų
Heavy Atom Count64
Formal Charge0
Complexity1630
Isotope Atom Count0
Defined Atom Stereocenter Count24
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes